ReviewFrontiers in microbiology2016
The Progress of Therapeutic Vaccination with Regard to Tuberculosis.
Review in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients.Nature communications · 2021Trial
- HowVaccines · 2026Review
- Gut microbiota and tuberculosis infection: interaction and therapeutic potential.Gut microbes · 2025Review
- Review
- Surveillance of Daughter Micronodule Formation Is a Key Factor for Vaccine Evaluation Using Experimental Infection Models of Tuberculosis in Macaques.Pathogens (Basel, Switzerland) · 2023Article
- Host microbiome in tuberculosis: disease, treatment, and immunity perspectives.Frontiers in microbiology · 2023Review
- Mouse Models forPathogens (Basel, Switzerland) · 2022Review
- Article
- Antibiotic Resistance toAntibiotics (Basel, Switzerland) · 2022Review
- Novel Candidate Microorganisms for Fermentation Technology: From Potential Benefits to Safety Issues.Foods (Basel, Switzerland) · 2022Review
- End-point definition and trial design to advance tuberculosis vaccine development.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic.Frontiers in immunology · 2022Review
- Therapeutic Vaccines for Tuberculosis: An Overview.Frontiers in immunology · 2022Review
- Article
- Heme oxygenase-1 inhibition promotes IFNγ- and NOS2-mediated control of Mycobacterium tuberculosis infection.Mucosal immunology · 2021Article
- B-Cells and Antibodies as Contributors to Effector Immune Responses in Tuberculosis.Frontiers in immunology · 2021Review
- Review
- The Pathogenesis of Tuberculosis-The Koch Phenomenon Reinstated.Pathogens (Basel, Switzerland) · 2020Review
- Enhanced tuberculosis clearance through the combination treatment with recombinant adenovirus-mediated granulysin delivery.Theranostics · 2020Article
- Single-Dose Mucosal Immunotherapy With Chimpanzee Adenovirus-Based Vaccine Accelerates Tuberculosis Disease Control and Limits Its Rebound After Antibiotic Cessation.The Journal of infectious diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A major problem with tuberculosis (TB) control is the long duration of drug therapy-both for latent and for active TB. Therapeutic vaccination has been postulated to improve this situation, and to this end there are several candidates already in clinical phases of development. These candidates follow two main designs, namely bacilli-directed therapy based on inactivated -whole or -fragmented bacillus (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.